Physician profile
Frederick Alan Klein
NPI 1962487876
$5,125.78
in general payments reported to CMS, 2019-2025
28 companies · $917 in 2025
The $917 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $552 · 2020: $307 · 2021: $717 · 2022: $697 · 2023: $839 · 2024: $1,097 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,852.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,413.88 | 2019-2025 | |
| Janssen Biotech, INC. | $471.30 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $435.60 | 2019-2025 | Entyvio, Eohilia |
| Celgene Corporation | $346.70 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $317.77 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Intercept Pharmaceuticals, INC. | $241.55 | 2019-2025 | Ocaliva |
| Qol Medical, LLC | $206.53 | 2019-2025 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $201.53 | 2021-2023 | |
| Ardelyx, INC. | $189.74 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $166.98 | 2022-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $161.59 | 2019-2024 | Rebyota |
| Ironwood Pharmaceuticals, INC | $136.75 | 2020-2024 | Linzess |
| Genzyme Corporation | $134.47 | 2022-2025 | |
| Braintree Laboratories, INC. | $86.17 | 2021-2024 | Suflave, Sutab |
| Pfizer INC. | $82.47 | 2023-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $70.26 | 2019 | |
| Gilead Sciences, INC. | $70.16 | 2021-2025 | |
| Biocon Biologics INC | $65.03 | 2024-2025 | Hulio, Yesintek |
| Celltrion USA INC. | $62.73 | 2024-2025 | Zymfentra, Vegzelma |
| Alfasigma USA, INC. | $44.28 | 2020 | |
| Allergan, INC. | $41.36 | 2019 | |
| Phathom Pharmaceuticals, INC. | $38.01 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $32.82 | 2024 | Resmetirom |
| Ipsen Biopharmaceuticals, INC | $31.56 | 2025 | Iqirvo |
| Redhill Biopharma INC. | $26.21 | 2022-2023 | |
| Lilly USA, LLC | $19.00 | 2024 | Omvoh |
| Amgen INC. | $18.31 | 2023 | Avsola, Amjevita |
| Daiichi Sankyo INC. | $13.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.